Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
Κύριος συγγραφέας: | Akter, Anika |
---|---|
Άλλοι συγγραφείς: | Alam, Marzia |
Μορφή: | Thesis |
Γλώσσα: | English |
Έκδοση: |
Brac University
2022
|
Θέματα: | |
Διαθέσιμο Online: | http://hdl.handle.net/10361/17039 |
Παρόμοια τεκμήρια
-
Biologics and Biosimilars as Treatment Options for Psoriasis
ανά: Moya, Amena Khatun
Έκδοση: (2023) -
Importance of biologics in rheumatoid arthritis management
ανά: Riyadh, S. M.
Έκδοση: (2022) -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
ανά: Afroza, Halima
Έκδοση: (2024) -
Importance of biologically active agents over other therapies in Rheumatoid Arthritis- a review
ανά: Mehreen, Elnaj
Έκδοση: (2021) -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
ανά: Islam, Nahidul
Έκδοση: (2023)